Post-COVID oncology


Published: 30 June 2020
Abstract Views: 303
PDF: 190
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • M. Rossi SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • G. Bellotti SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • F. Blengio SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • V. Fusco SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • P. Guglielmini SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • R. Manfredi SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • P. Piovano SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • E. Traverso SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • M. Vincenti SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • S. Zai SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • A. Pertino SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • M. Alessio SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • I. De Martino SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • G. Piacentini SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • A. Ghiglione SC Oncologia, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • E. Ferrero Day Hospital Onco-ematologico, Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.

Objectives: To analyse the organisational changes adopted by the Oncology SC during the Covid-19 emergency in order to identify their future applicability as an ordinary model of oncology patient management. Methodology: Application of ministerial recommendations, of the Piedmont and Aosta Valley Oncology Network and of the main scientific societies on the management of oncological patients during the pandemic and in phase 2. Results: During the pandemic, organisational models and pathways were adopted that ensured continuity of care and patient safety and can also be applied in the post-Covid phase. Conclusions: The reorganisation model of Oncology during the Covid-19 emergency was effective and some of the pathways adopted may constitute an ordinary tool of activity.


Rossi, M., Bellotti, G., Blengio, F., Fusco, V., Guglielmini, P., Manfredi, R., Piovano, P., Traverso, E., Vincenti, M., Zai, S., Pertino, A., Alessio, M., De Martino, I., Piacentini, G., Ghiglione, A., & Ferrero, E. (2020). Post-COVID oncology. Working Paper of Public Health, 8(1). https://doi.org/10.4081/wpph.2020.9245

Downloads

Download data is not yet available.

Citations


Most read articles by the same author(s)